SAN
JOSE, Calif., Sept. 19,
2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa"
or the "Company") (NASDAQ: ANIX), a biotechnology company focused
on the treatment and prevention of cancer, today announced that it
has established a Cancer Business Advisory Board (CBAB), whose
purpose is to provide guidance on the Company's clinical and
business development initiatives. The CBAB will be co-chaired by
Anixa Chairman and CEO, Dr. Amit
Kumar, and Board Director, Dr. Arnold Baskies, and will include the following
members:
- Dr. Kevin Cullen, MD: the
Marlene and Stewart Greenebaum Distinguished Professor of Oncology
at University of Maryland School of
Medicine (UMSOM), Director of the University of Maryland Marlene and Stewart
Greenebaum Comprehensive Cancer Center and the Program in Oncology
at the UMSOM, and former Chairman of the National Board of
Directors of the American Cancer Society (ACS) for 2018.
- Dan Heist: Director of
Internal Audit at Penn State and former
Chairman of the National Board of Directors of the American Cancer
Society for 2019.
- Dr. Karen E. Knudsen, MBA,
PhD: current CEO of the American Cancer Society and the
American Cancer Society Cancer Action Network (ACS CAN). Dr.
Knudsen is the first research oncologist and first female CEO of
the American Cancer Society. Dr. Knudsen was recently elected by
Forbes Magazine to its list of 50 Over 50—a list of the most
impactful people over 50.
- Dr. Len Lichtenfeld, MD,
MACP: medical oncologist and former Chief Medical and
Scientific Officer, and Deputy Chief Medical Officer of the
American Cancer Society.
- Michael T. Marquardt: CEO
of Global Kompass Strategies, CEO of Epi One, and the former
Chairman of the National Board of Directors of the American Cancer
Society for 2022.
- Scarlott Mueller, MPH, RN,
FAAN: Board Member of the International Society of Nurses in
Cancer and former Chairperson of the National Board of Directors of
the American Cancer Society for 2016.
- Gary Reedy: Chairman of
the Center for Global Health Innovation, former CEO of the American
Cancer Society and the ACS CAN from 2014 to 2020, and former
Chairman of the National Board of Directors of the American Cancer
Society for 2013.
- Rob Youle, JD: President
of Iowa Law School Foundation and former Chairman of the National
Board of Directors of the American Cancer Society for 2015.
"We are thrilled to welcome such an impressive roster of highly
accomplished individuals as members of our newly established CBAB,"
said Dr. Kumar. "In addition to devoting many years to advocate for
cancer patients and their families, each member brings a wealth of
knowledge and a broad network of contacts that will be invaluable
to Anixa as we progress the development of our cancer vaccines and
immunotherapies. We believe the caliber of the CBAB's inaugural
members is a testament to the strength and potential of our
technology, and we look forward to their insights as we pursue
clinical and business development initiatives."
Dr. Baskies, Anixa Board Director and former Chairman of the
National Board of Directors of the American Cancer Society for
2017, stated, "All of these individuals have been colleagues of
both me and Dr. Kumar for many years as we worked in leadership and
board roles at the American Cancer Society, which is the largest
non-profit organization comprehensively battling cancer. Each of
these colleagues has devoted decades of their lives to cancer, and
each is very passionate about preventing cancer, improving
therapies, and broadly helping to eliminate cancer as we know it.
To my knowledge, this is the first time that such an august group
has come together in the private sector to help change the world,
which is our goal at Anixa."
Dr. Cullen is the Marlene and Stewart Greenebaum Distinguished
Professor in Oncology and Director of the Program in Oncology at
the UMSOM. He also serves as director of the University of Maryland Marlene and Stewart
Greenebaum Comprehensive Cancer Center. In 2011, Dr. Cullen was
appointed by President Obama to a five-year term as a member of the
National Cancer Advisory Board, an advisory committee to the NCI.
He previously served as Chairman of the Board of ACS and is a
recipient of the ACS Excellence in Research Award. Dr. Cullen
received his medical degree from Harvard
Medical School. He conducted his residency in internal
medicine at Beth Israel Hospital in Boston, MA, and fellowship in oncology with
the NCI in Bethesda, MD.
Mr. Heist has been the Director of Internal Audit at
Penn State since 2003, bringing more
than 30 years of auditing and accounting experience. He is active
with ACS, serving at the local, state, and national level; and is a
past Chairman of the Board of ACS. Previously, Mr. Heist was a
Senior Manager at Deloitte & Touche, LLP, and served a variety
of both privately and publicly held manufacturing and service
industry clients. He received a bachelor of science degree from
Penn State.
Dr. Knudsen has been the CEO of ACS and its advocacy affiliate,
ACS CAN, since 2021. She previously served as Executive Vice
President of Oncology Services and Enterprise Director for Sidney
Kimmel Cancer Center at Jefferson Health; President for the
Association of American Cancer Institutes, representing the 102
leading cancer centers in North
America; and on the board of directors of the American
Association for Cancer Research. Dr. Knudsen serves on the board of
advisors for the National Cancer Institute (NCI) and on 12 external
advisory boards for NCI-designated cancer centers. She is an active
member of several committees with the American Society for Clinical
Oncology, in addition to serving on other academic and for-profit
advisory boards. Dr. Knudsen holds a bachelor's degree in biology
from George Washington University, a
PhD in biological sciences from the University
of California San Diego, and an MBA from Temple University Fox School of Business.
Dr. Lichtenfeld is an experienced medical oncologist and
independent consultant with an extensive background in cancer care,
cancer research, healthcare policy, and physician payment. He is a
member of the CancerCare board of directors, and an advisor to
several early-stage patient- and cancer-focused companies,
including Trialjectory and OneHealth. Dr. Lichtenfeld was
previously the Chief Medical and Scientific Officer, and Deputy
Chief Medical Officer for ACS. He received a bachelor's degree in
sociology from the University of
Pennsylvania, a medical degree from Hahnemann Medical
College (now Drexel University College
of Medicine) and medical training at Temple
University, Johns Hopkins and
the NCI.
Mr. Marquardt is the CEO of Global Kompass Strategies, serving
as a global advisor to corporations around the world; and CEO of
Epi One, a biotech company building a new cancer diagnosis
platform. He previously led several companies in the technology and
healthcare sectors, and served as President of the global risk
management firm founded by former FBI Director Louis J. Freeh. Mr. Marquardt has served on the
ACS and ACS CAN boards of directors since 2018 and 2014,
respectively, and formerly as Chair of the former ACS South
Atlantic Division Board and Chairman of the ACS National Board. He
received ACS's St. George National Award in 2017, and was appointed
in January 2022 by President Biden to
serve on the U.S. Commission for the Preservation of America's
Heritage Abroad. Mr. Marquardt received a bachelor's degree in
medical biology, humanities from the University of New England; and a master's degree in
chemistry from the University of
Virginia.
Ms. Mueller currently serves on the board of the International
Society of Nurses in Cancer Care and has volunteered with ACS and
ACS CAN for more than 35 years. She has held numerous leadership
positions at ACS, including service as board President/Chair of the
former Florida Division and Chair of the ACS board of directors.
Ms. Mueller served 21 years as the Vice President and Chief Nursing
Officer for the North Florida Regional Medical Center, and
previously served on the boards of various organizations, including
the Oncology Nursing Society Foundation, Samaritan Counseling
Center of North Central Florida, the Oncology Nursing Certification
Corporation, and the Oncology Nursing Society-Nominating Committee.
Ms. Mueller received a master's degree in public health and a
bachelor of science in nursing degree from the University of North Carolina at Chapel Hill.
Mr. Reedy was CEO of ACS and ACS CAN from 2015 to 2021,
following 15 years of volunteer leadership, including chairing the
boards of directors for the organizations. He previously served as
Worldwide Vice President, Government Affairs and Policy at Johnson
& Johnson, President of Ortho Biotech, and in senior leadership
roles at SmithKline Beecham and Centocor. He holds appointments to
the board of directors of the Center for Global Health Innovation,
the board of councilors for The Carter Center, the Georgia Tech
Advisory Board, the Dean's Council
at Emory University's Rollins School of Public Health, the Advisory
Board for Emory University's Center for
Ethics, and the MMM Tech Advisory Council. Mr. Reedy graduated from
Emory & Henry College and received
an honorary Doctorate of Humane Letters from Arcadia University.
Mr. Youle is a civil practice attorney based in Denver, Colorado. He was a volunteer for ACS
for nearly 30 years, serving at the local, state, regional and
national levels. Mr. Youle served as Chairman of the Board of ACS's
former Colorado and Rocky Mountain
Divisions, its Great West Division and ACS CAN. He served on the
ACS National Board since 2006 and was Chairman in 2015. Mr. Youle
received a bachelor of science degree in finance from the Gies
College of Business - University of Illinois
Urbana-Champaign, and a Juris Doctor degree from
University of Iowa College of Law.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the
treatment and prevention of cancer. Anixa's therapeutic portfolio
consists of an ovarian cancer immunotherapy program being developed
in collaboration with Moffitt Cancer Center, which uses a novel
type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T)
technology. The Company's vaccine portfolio includes a novel
vaccine being developed in collaboration with Cleveland Clinic to
prevent breast cancer – specifically triple negative breast cancer
(TNBC), the most lethal form of the disease – as well as a vaccine
to prevent ovarian cancer. These vaccine technologies focus on
immunizing against "retired" proteins that have been found to be
expressed in certain forms of cancer. Anixa's unique business model
of partnering with world-renowned research institutions on clinical
development allows the Company to continually examine emerging
technologies in complementary fields for further development and
commercialization. To learn more, visit www.anixa.com or follow
Anixa on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are not statements of historical facts, but rather
reflect Anixa's current expectations concerning future events and
results. We generally use the words "believes," "expects,"
"intends," "plans," "anticipates," "likely," "will" and similar
expressions to identify forward-looking statements. Such
forward-looking statements, including those concerning our
expectations, involve risks, uncertainties and other factors, some
of which are beyond our control, which may cause our actual
results, performance or achievements, or industry results, to be
materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. These risks, uncertainties and factors include, but are
not limited to, those factors set forth in "Item 1A - Risk Factors"
and other sections of our most recent Annual Report on Form 10-K as
well as in our Quarterly Reports on Form 10-Q and Current Reports
on Form 8-K. We undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
You are cautioned not to unduly rely on such forward-looking
statements when evaluating the information presented in this press
release.
Contacts:
Stephen Kilmer
Investor Relations
skilmer@anixa.com
646-274-3580
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download
multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-establishes-cancer-business-advisory-board-301931654.html
SOURCE Anixa Biosciences, Inc.